Navigation Links
EntreMed Reports Second Quarter 2012 Financial Results
Date:8/14/2012

ROCKVILLE, Md., Aug. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2012. 

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

EntreMed reported a net loss for the second quarter of 2012 of ($10.5 million), or ($0.56) per share. This compares with a net loss of ($1.7 million), or ($0.17) per share, for the same period last year.
For the first six months of 2012 the reported net loss was ($13.0 million), or ($0.86) per share as compared to ($4.3 million), or ($0.41) per share for 2011.  The 2012 net loss amounts included non-cash interest charges associated with our Strategic Financing totaling $9.2 million and $10.0 million for the three and six months ended June 30, 2012, respectively.  Excluding the non-cash interest, net loss for the second quarter and first six months of 2012 was ($1.3 million), or ($0.07) per share and ($3.0 million) or ($0.19) per share, respectively.

As of June 30, 2012, EntreMed had cash and cash equivalents of approximately $10.1 million.

Sara B. Capitelli, EntreMed's Vice President, Finance & Principal Accounting Officer, commented on the second quarter results, "Our second quarter 2012 financial results were in line with expectations.  Our research and development expenses for the second quarter decreased compared to the previous year as we completed enrollment of patients in the ENMD-2076 Phase 2 ovarian cancer study in 2011.  We anticipate third and fourth quarter operating expenses to increase as we execute on our clinical development plan in the US and China."

Ken Ren, PhD, EntreMed's Chief Executive Officer, further commented, "We continue to move forward with our clinical development of ENMD-2076.  As previously announced, we recently initiated and are recruiting patients for a Phase 2 trial in triple negative breast cancer and are currently in the process of planning additional trials in other targeted indications. In addition, our China operations and local development activities are up and running; these are all steps towards executing our global development plans." 

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission ("SEC"), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com ENTREMED, INC.SUMMARY OF OPERATING RESULTS(Unaudited)Three Months Ended June 30,2012

2011Total revenues$$
8,852Research and development696,287

949,706General and administrative601,502

719,898Interest Expense9,165,429

0Net loss(10,463,218)

(1,658,259)Net loss per share (basic and diluted)$
(0.56)

$
(0.17)attributable to common shareholdersWeighted average number of shares outstanding18,979,559

11,506,736(basic and diluted)Six Months Ended June 30,2012

2011Total revenues$$
8,852Research and development1,257,536

2,347,980General and administrative1,698,248

1,973,003Interest Expense10,041,292

0Net loss(12,997,076)

(4,254,638)Net loss per share (basic and diluted)$
(0.­­86)

$
(0.41)attributable to common shareholdersWeighted average number of shares outstanding 

15,568,841

11,475,997(basic and diluted)Cash and cash equivalents$10,058,935

$3,800,820 


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
2. EntreMed Reports First Quarter 2012 Financial Results
3. Nile Therapeutics Reports 2012 Second Quarter Financial Results
4. PDI Reports 2012 Second Quarter Financial Results
5. Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results
6. Patient Safety Technologies Reports Second Quarter 2012 Results
7. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):